Please login to the form below

Not currently logged in
Email:
Password:

Par buys Anchen in $410m deal

US-based Par Pharmaceutical is to purchase generic medicines manufacturer Anchen Pharmaceuticals

Par Pharmaceutical Companies is to acquire Anchen Pharmaceuticals, a privately owned speciality pharmaceutical company focused on developing and commercialising extended release and niche generic products, for $410m (€283.6m) in cash.

California-based Anchen has five commercialised products, 27 abbreviated new drug applications (ANDAs) on file with the US Food and Drugs Administration (FDA), five of which are believed to be first-to-file and has 26 additional products in development. Anchen also anticipates launching up to 10 niche generic products during the next two years.

Patrick G LePore, chairman, chief executive and president of Par, said: "This transaction accelerates the expansion of Par's research and development infrastructure and reinforces our strategy to provide long-term sustainable growth. Anchen has an excellent development track record and robust product pipeline, which, when combined with Par's existing capabilities and pipeline, more than doubles our product opportunities."

The acquisition is subject to conditions and approvals and is expected to be complete by the end of the year.

25th August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics